Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Effexor Sales Growth Far Outpacing Antidepressant Class, Wyeth Says

This article was originally published in The Pink Sheet Daily

Executive Summary

Venlafaxine sales "value and volume" are growing two to three times the market rate for antidepressants, Exec VP Poussot says. Growth has been spurred by international sales; Effexor sales volume rose 2% in the U.S. during the first half of 2005.

You may also be interested in...



Generic Effexor XR Could Hit Antidepressant Market By June 2008

Wyeth and Teva settle patent infringement suit; Teva believes it holds 180-day exclusivity for generic extended-release venlafaxine.

Generic Effexor XR Could Hit Antidepressant Market By June 2008

Wyeth and Teva settle patent infringement suit; Teva believes it holds 180-day exclusivity for generic extended-release venlafaxine.

Antidepressant Market Will Remain Flat In Face Of Adult Suicidality Concerns, Forest Says

The impact of media attention on the adult suicide issue will be “hard to predict,” President & COO Goodman says. Forest expects FDA action on a Namenda supplemental NDA for mild-to-moderate Alzheimer’s in the next few weeks.

Related Content

Topics

UsernamePublicRestriction

Register

PS078529

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel